A Phase 3 Study of Taletrectinib versus Placebo in People with Non-Small Cell Lung Cancer After Complete Tumor Removal

Full Title

A Phase 3 Multicenter Double-Blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection (Advarra)

Purpose

Researchers are comparing taletrectinib with a placebo (inactive drug) in people with non-small cell lung cancer (NSCLC). The people in this study have stage 1B-3A NSCLC that has a ROS1 gene fusion. They have had the tumor completely removed with surgery.

If you take part in this study, you will be randomly assigned to get taletrectinib or a placebo. You will take the treatment for up to 3 years, or unless your cancer gets worse. Both taletrectinib and the placebo are capsules taken orally (by mouth).

Contact

For more information about this study or to see if you can join, please call 646-888-4226.